N-Aryl (thio) anthranilic acid amide derivatives, their...

Details N-Aryl (thio) anthranilic acid amide derivatives, their... N-Aryl (thio) anthranilic acid amide derivatives, their...

2006-02-21

2006-02-21

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S346100, C514S396000

Reexamination Certificate

active

07002022

ABSTRACT:
Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9and R10are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2is aryl; R2is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2cannot represent 2-phthalimidyl, and in case of Y=SO2cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5and R6, independently of the other, is H or a substituent other than hydrogen; and R7and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

REFERENCES:
patent: 3226394 (1965-12-01), Schipper
patent: 19830430 (2000-01-01), None
patent: 0 947 500 (1999-10-01), None
patent: 1189719 (1970-04-01), None
patent: 56-161362 (1981-12-01), None
patent: 9-59236 (1997-03-01), None
patent: 9059236 (1997-03-01), None
patent: 10-259176 (1998-09-01), None
patent: 96/09294 (1996-03-01), None
patent: 96/41795 (1996-12-01), None
patent: 98/17648 (1998-04-01), None
patent: 95/25723 (1998-09-01), None
patent: 99/32477 (1999-07-01), None
patent: 99/54284 (1999-10-01), None
Japan Tobacco Inc., Chemical Abstracts, 1982; 162351, (JP 56-161362, Dec. 11, 1981).
Inaba et al., Chemical Abstracts 129:310895, Jun. 4, 1999, ( JP 10-259176, Sep. 29, 1998).
Augustin, tiPS. vol. 19, “Antiangiogenic tumour therapy: will it work?” pp. 216-222, (Jun. 1998).
Hisano et al. Chem. Pharm.Bull., vol. 20, No. 12, “Syntheses and Pharmacological Activities of 2-Heterocyclic Substituted 4(3H)-Quinazolinone Derivatives,” pp. 2575-2584, (1972).
Lüddens et al., European Journal of Pharmacology, vol. 344, “Structure—activity relationship of furosemide-derived compounds as antagonists of cerebellum-specific GABAAreceptors,” pp. 269-277, (1998).
Caplus, English Abstract JP9059236, Kawagoe Keiichi, Mar. 1997.
Breier et al., Trends in Cell Biology, vol. 6, “The Role of Vascular Endothelial Growth Factor in Blood Vessel Formation,” pp. 454-456, (Dec. 1996).
Mikhailitsyn et al. Chemical Abstracts, vol. 116, 417373f, p. 771, (1992) XP-002128306.
Shani et al., Pharmacology, vol. 26, “Structure Activity Correlation for Diuretic Furosemide Congeners,” pp. 172-180, (1983).
Tiwari et al., J.Chem.Soc.Pak, vol. 4, No. 2, “Visible Antifertility Compounds—Part IV: Syntheses of 2-(Phthallmido methylamino)-substituted benzanilides,” pp. 115-117, (1982).
Varnavas et al., Pharmazie, vol. 51, “Anthranoyl-anthranilic acid: a template for the development of a new class of chloecystokinin receptor ligands,” pp. 697-700, (1996).
The Condensed Chemical Dictionary, Fifth Edition, p. 114 (1956).

Affiliated with

Also associated with

Rating

N-Aryl (thio) anthranilic acid amide derivatives, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-Aryl (thio) anthranilic acid amide derivatives, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-Aryl (thio) anthranilic acid amide derivatives, their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3636452